Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Plus Standard Treatment for High-Risk Prostate Cancer
NCT00116142Phase 3Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2005
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Jun 2005; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00116142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116142.